论文部分内容阅读
美国每年要进行70万例子宫切除术,其并发症率为20～66%,多数是术后感染。为确定选择性非根治性子宫切除术间应用头V对预防盆腔及创口感染的效果,作者对86例经阴道子宫切除术者(简称阴切组)及429例经腹部子宫切除术者(腹切组)进行随机、双盲、对照的临床试验。头Ⅴ用法:术前1～2小时肌注1 g,其后6及12小时再肌注1次,或给予相同剂量安慰剂进行对照。结果发现:如包括所有创口感染在内,此法能使盆腔及创口感染率下降33%;如仅包括创口化脓,则可下降42%,均有统计学意义。
The United States has to carry out 700,000 cases of hysterectomy each year, with a complication rate of 20 to 66%, most of which are postoperative infections. In order to determine the effect of head V on the prevention of pelvic and wound infection in patients with selective non-radical hysterectomy, 86 cases of transvaginal hysterectomy (oxytocin group) and 429 cases of transabdominal hysterectomy Group) were randomized, double-blind, controlled clinical trials. The first Ⅴ usage: intraoperative 1 to 2 hours before intramuscular injection of 1 g, followed by 6 and 12 hours and then intramuscular injection 1, or given the same dose of placebo for control. The results showed that: If including all wound infections, this method can reduce the pelvic and wound infection rate of 33%; if only including wound suppuration, you can drop 42%, were statistically significant.